ASX:ACW

ACTINOGEN MEDICAL LIMITED

ACTINOGEN MEDICAL LIMITED has not announced any capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise

< $50k

Investors Interested in Next Raise

< 10

How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

2. View Terms

View the full term sheet for the capital raise.

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

Company Overview

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

Type

Listed Company

GICS Sub-industry

Biotechnology

Head Office

Suite 901a, Level 9/109 Pitt St, Sydney NSW 2000, Australia

Website

www.actinogen.com.au

Medical

Biotechnology

Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.